Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 113617-63-3
2. Orbax
3. Nsc-758614
4. 660932tpy6
5. 1-cyclopropyl-7-[(3s,5r)-3,5-dimethylpiperazin-1-yl]-5,6,8-trifluoro-4-oxoquinoline-3-carboxylic Acid
6. 3-quinolinecarboxylic Acid, 1-cyclopropyl-7-[(3r,5s)-3,5-dimethyl-1-piperazinyl]-5,6,8-trifluoro-1,4-dihydro-4-oxo-, Rel-
7. Ncgc00160518-01
8. Dsstox_cid_26201
9. Dsstox_rid_81432
10. Dsstox_gsid_46201
11. 1-cyclopropyl-7-((3s,5r)-3,5-dimethylpiperazin-1-yl)-5,6,8-trifluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid
12. 1-cyclopropyl-7-[(3r,5s)-3,5-dimethylpiperazin-1-yl]-5,6,8-trifluoro-4-oxoquinoline-3-carboxylic Acid
13. Smr000544203
14. Cp-104354
15. Orbifloxacin [inn]
16. Cas-113617-63-3
17. Sr-01000790054
18. Orbifloxacin [usp:inn:ban]
19. Mfcd00864858
20. Unii-660932tpy6
21. 1-cyclopropyl-7-((3r,5s)-3,5-dimethylpiperazin-1-yl)-5,6,8-trifluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid
22. Specplus_000366
23. Cp 104354
24. Orbifloxacin (usp/inn)
25. Orbifloxacin [mi]
26. Orbax [veterinary] (tn)
27. Orbifloxacin [jan]
28. Orbifloxacin Impurity Mixture
29. Orbifloxacin [mart.]
30. Mls000766847
31. Mls001216436
32. Divk1c_006462
33. Orbifloxacin [usp-rs]
34. Schembl125116
35. Chembl295433
36. Dtxsid7046201
37. Kbio1_001406
38. Orbifloxacin [green Book]
39. Chebi:183823
40. Hms2875g03
41. Hms3264m13
42. Pharmakon1600-01503711
43. Orbifloxacin [usp Impurity]
44. Bcp18829
45. Hy-b0915
46. Rkl10078
47. Zinc3882891
48. Orbifloxacin [usp Monograph]
49. Tox21_111867
50. Nsc758614
51. S4150
52. Akos015969739
53. Tox21_111867_1
54. Ccg-213832
55. Cs-4384
56. Db11443
57. Ks-5013
58. Nsc 758614
59. Orbifloxacin 100 Microg/ml In Methanol
60. Ncgc00160518-02
61. Ncgc00160518-03
62. Ncgc00160518-04
63. 1-cyclopropyl-5,6,8-trifluoro-1,4-dihydro-7-(cis-3,5-dimethyl-1-piperazinyl)-4-oxo-quinoline-3-carboxylic Acid
64. Sbi-0207085.p001
65. Orbifloxacin 100 Microg/ml In Acetonitrile
66. O0516
67. D08299
68. D91881
69. O-2950
70. Ab00833179_04
71. Ab00833179_05
72. Orbifloxacin, Vetranal(tm), Analytical Standard
73. A803076
74. Orbifloxacin, Antibiotic For Culture Media Use Only
75. Q7100015
76. Sr-01000790054-2
77. Sr-01000790054-3
78. Brd-k63001556-001-03-9
79. Orbifloxacin, European Pharmacopoeia (ep) Reference Standard
80. Orbifloxacin, United States Pharmacopeia (usp) Reference Standard
81. 1-cyclopropyl-5,6,8-trifluoro-7-(cis-3,5-dimethyl-1-piperazinyl)-1,4-dihydro-4-oxoquinoline-3-carboxylic Acid
82. 1-cyclopropyl-7-(cis-3,5-dimethyl-1-piperazinyl)-5,6,8-trifluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic Acid
83. 1-cyclopropyl-7-(cis-3,5-dimethyl-1-piperazinyl)-5,6,8-trifluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic Acid
84. 1-cyclopropyl-7-(cis-3,5-dimethylpiperazin-1-yl)-5,6,8-trifluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid
85. 1-cyclopropyl-7-[(3r,5s)-3,5-dimethylpiperazin-1-yl]-5,6,8-trifluoro-4-oxo-quinoline-3-carboxylic Acid
86. 1-cyclopropyl-7-[(3r,5s)-3,5-dimethylpiperazin-4-ium-1-yl]-5,6,8-trifluoro-4-oxoquinoline-3-carboxylate
87. 1-cyclopropyl-7-[(3s,5r)-3,5-dimethylpiperazin-1-yl]-5,6,8-triluoro-4-oxoquinoline-3-carboxylic Acid
Molecular Weight | 395.4 g/mol |
---|---|
Molecular Formula | C19H20F3N3O3 |
XLogP3 | 0.9 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 9 |
Rotatable Bond Count | 3 |
Exact Mass | 395.14567599 g/mol |
Monoisotopic Mass | 395.14567599 g/mol |
Topological Polar Surface Area | 72.9 Ų |
Heavy Atom Count | 28 |
Formal Charge | 0 |
Complexity | 691 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Related Excipient Companies
Excipients by Applications
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Orbifloxacin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Orbifloxacin, including repackagers and relabelers. The FDA regulates Orbifloxacin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Orbifloxacin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Orbifloxacin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Orbifloxacin supplier is an individual or a company that provides Orbifloxacin active pharmaceutical ingredient (API) or Orbifloxacin finished formulations upon request. The Orbifloxacin suppliers may include Orbifloxacin API manufacturers, exporters, distributors and traders.
click here to find a list of Orbifloxacin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Orbifloxacin DMF (Drug Master File) is a document detailing the whole manufacturing process of Orbifloxacin active pharmaceutical ingredient (API) in detail. Different forms of Orbifloxacin DMFs exist exist since differing nations have different regulations, such as Orbifloxacin USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Orbifloxacin DMF submitted to regulatory agencies in the US is known as a USDMF. Orbifloxacin USDMF includes data on Orbifloxacin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Orbifloxacin USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Orbifloxacin suppliers with USDMF on PharmaCompass.
Orbifloxacin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Orbifloxacin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Orbifloxacin GMP manufacturer or Orbifloxacin GMP API supplier for your needs.
A Orbifloxacin CoA (Certificate of Analysis) is a formal document that attests to Orbifloxacin's compliance with Orbifloxacin specifications and serves as a tool for batch-level quality control.
Orbifloxacin CoA mostly includes findings from lab analyses of a specific batch. For each Orbifloxacin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Orbifloxacin may be tested according to a variety of international standards, such as European Pharmacopoeia (Orbifloxacin EP), Orbifloxacin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Orbifloxacin USP).
LOOKING FOR A SUPPLIER?